TIDMLMT
Lombard Medical Technologies PLC
04 March 2010
?
Press information
Lombard Medical Technologies PLC
("Lombard" or "Company")
International Congress (XXIII) Endovascular Interventions
London, UK, 4 March 2010 - Lombard Medical Technologies PLC (AIM: LMT), a
medical device company focused on device solutions for $1 billion dollar
abdominal aortic aneurysm repair market, announces that Dr Peter Phillips, the
Company's Chief Technology Officer and co-inventor of the Aorfix(TM) implant,
has presented data on the use of Aorfix(TM) at the International Congress
(XXIII) Endovascular Interventions in Phoenix, Arizona (1-4th March).
The data presented was from Lombard's Retrospective Aorfix(TM) Data Retrieval
("RADAR") voluntary registry for all Aorfix(TM) customers. Dr Phillips stated
that the Aorfix(TM) device has been utilized in the largest series of patients
with difficult and tortuous anatomy ever studied, yet still had outstanding
clinical results, highlighted by a very low incidence of stent migration (0%),
wire fracture (<0.25%) and graft limb occlusion (<0.25%) at 12 months in the
data set of 461 eligible patients
In the session attended by many of the leading vascular interventionalists in
the country, Dr Phillips also gave a brief update on recruitment into Lombard's
pivotal FDA study for Aorfix(TM) in which he stated that, to date, more than 175
patients had been recruited into the trial, and that the Company requires 160
patients with follow-up to 12 months for submission to the FDA (minimum 40 low
angle and 120 high angle). The Company has now recruited patients in excess of
the minima and is on track to have the required number of patients with
appropriate follow-up completed during the first half of 2011.
- Ends -
For further information:
+---------------------------------------+----------------------+
| | |
| Lombard Medical Technologies PLC | |
+---------------------------------------+----------------------+
| Simon Neathercoat, Non-executive | Tel: 01235 750 800 |
| Chairman | |
| John Rush, Chief Executive Officer | |
| Tim Hall, Finance Director | |
+---------------------------------------+----------------------+
| | |
| Evolution Securities Limited | |
+---------------------------------------+----------------------+
| Barry Saint | Tel : 020 7071 4300 |
| Tim Redfern | |
| Esther Lee | |
+---------------------------------------+----------------------+
| | |
| Financial Dynamics | |
+---------------------------------------+----------------------+
| Jonathan Birt | Tel : 020 7831 3113 |
| Susan Quigley | |
+---------------------------------------+----------------------+
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, Aorfix(TM), is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of
the aorta which, if untreated, may rupture and cause death. Approximately 4.5
million people are living with AAA in the developed world and each year 600,000
new cases are diagnosed. The market for endovascular stent grafts for the
treatment of AAA is currently worth approximately $900 million and is expected
to grow to around $1.6 billion by 2015. Aorfix(TM) is currently being
commercialised in the EU, with a pivotal clinical trial ongoing in the USA.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and
Boston, USA.
Further background on the Company can be found at www.lombardmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAEDLEEFEEEF
| 
